EICHORCondition: NSCLC (advanced Non-small Cell Lung Cancer) · Stage IV Lung Cancer · Sponsor: Inhatarget Therapeutics
The combination of chemotherapy and immunotherapy shows promising results in terms of overall survival (OS) and progression-free survival (PFS) for the treatment of first-line stage IV non-small cell lung cancer (NSCLC) patients, leading to such combinations becoming a real backbone of the Standard of Care (SoC) for NSCLC patients. However, conventional chemotherapy's severe systemic toxicities represent a limiting factor in terms of administered dose and frequency. Administration of cisplatin by inhalation (pulmonary route) is a promising additional approach that may overcome the limitations of conventional chemotherapy. Use of a dry powder inhaler enables a high therapeutic response by delivering high local concentrations of a well-established active substance without the usual undesired reactions that limit the use of high doses when administered through the conventional systemic route. This study may provide insights into whether this add-on treatment might be a safe and potentially efficacious option for NSCLC patients.
This description comes directly from the study's public registry record.
Frédéric De Coninck · +32 (0) 484 71 37 73 · frederic.de.coninck@inhatarget.com
Wendy Sonnet, MSc, PhD · wendy.sonnet@inhatarget.com
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet - Hôpital Universitaire de Bruxelles | Brussels, Belgium | Recruiting |
| GHDC | Charleroi, Belgium | Recruiting |
| CHU Helora - Site Jolimont | Jolimont, Belgium | Recruiting |
| AZ Groeninge | Kortrijk, Belgium | Recruiting |
| CHU Sart Tilman | Liège, Belgium | Recruiting |
| CHU Ambroise Paré | Mons, Belgium | Recruiting |
| AZ Delta | Roeselare, Belgium | Recruiting |
| Université Paris-Saclay, UVSQ, APHP - Hôpital Ambroise Paré | Boulogne-Billancourt, France | Not Yet Recruiting |
| Centre François Baclesse de Caen | Caen, France | Not Yet Recruiting |
| Hôpital Européen Georges Pompidou, Paris-Cite University | Paris, France | Not Yet Recruiting |
| L'Institut de Cancérologie de l'Ouest | Saint-Herblain, France | Not Yet Recruiting |
| Instituto Oncologico Dr Rosell, Hospital Universitario Dexeus | Barcelona, Spain | Recruiting |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06896890